Evotec SE
Evotec SE (EVO): 1 pipeline candidate · ~5 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
5.3 months
0% dilution
Lead: Phase 1
1 candidate
N/A
N/A
A transparent, data-derived signal for Evotec SEacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$955.5M
Cash
$306.4M
Quarterly Burn
$239.1M
Runway
5.3 mo
Revenue
$797.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| Monoclonal antibody JST-010 | Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
43
Total value held
$5.8M
| Holder | Shares | Value |
|---|---|---|
| wcm investment management, llc | 627,260 | $1.5M |
| abc arbitrage sa | 509,050 | $1.3M |
| optiver holding b.v. | 283,576 | $709K |
| morgan stanley | 259,744 | $649K |
| envestnet asset management inc | 119,409 | $299K |
| millennium management llc | 99,568 | $249K |
| citadel advisors llc | 87,180 | $218K |
| pathstone holdings, llc | 34,127 | $85K |
| fore capital, llc | 31,355 | $78K |
| snowden capital advisors llc | 24,409 | $61K |
Showing top 10 of 43 institutional holders of Evotec SE. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Evotec SE's pipeline?
Evotec SE (EVO) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Evotec SE's lead drug candidate?
Evotec SE's most advanced tracked candidate is Monoclonal antibody JST-010 (Phase 1) for Pre-exposure Prophylaxis Against Pneumonic Plague in Healthy Adults.
What is Evotec SE's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Evotec SE has approximately 5.3 months of cash runway.
What is Evotec SE's market capitalization?
Evotec SE's market capitalization is approximately $955.5M.
Who is the CEO of Evotec SE?
Dr. Christian Wojczewski Ph.D. is the chief executive officer of Evotec SE (EVO).
Get the full picture on Evotec SE
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.